Product logins

Find logins to all Clarivate products below.


Hospital-Treated Gram-Negative Infections | Current Treatment: Physician Insights | US | 2024

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with such agents, and thus branded products like Allergan / AbbVie’s Avycaz, Shionogi’s Fetroja, Paratek Pharmaceuticals’ Nuzyra, Merck & Co.’s Recarbrio, Innoviva / Entasis’s Xacduro, Tetraphase Pharmaceuticals’ Xerava, Cipla Therapeutics’ Zemdri, and Merck & Co.’s Zerbaxa are typically restricted to later lines of therapy. Yet, increasing rates of antimicrobial resistance have created the need for safer products to effectively treat drug-resistant GNIs. In this analysis, we explore brand use in this market based on factors such as activity against key drug-resistant pathogens. Furthermore, hospital-based GNI specialists offer insight into how they treat GNIs in response to growing drug resistance.

QUESTIONS ANSWERED

  • What are the most prescribed first-, second-, and third-line therapies for inpatients with urinary tract infections, nosocomial pneumonia, or complicated intra-abdominal infections?
  • How are physicians approaching the treatment of infections caused by drug-resistant pathogens?
  • Which clinical and nonclinical factors drive, and limit, the prescribing of branded agents such as Avycaz, Zerbaxa, Zemdri, Xerava, and Nuzyra?
  • What will be the impact of recently approved agents such as Xacduro? What will drive use of such therapies, and in which infection types will they be used? Which current agents will be most affected?

PRODUCT DESCRIPTION Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

CONTENT HIGHLIGHTS

Geography: United States

Primary research: Survey of 100 U.S. hospital-based infectious disease and critical care specialists

Key drugs covered: Avycaz, Fetroja, Nuzyra, Recarbrio, Xacduro, Xerava, Zemdri, Zerbaxa

Related Market Assessment Reports

Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…